

Supplementary data

Table 1 of the supplementary data. Major inclusion and exclusion criteria in the BIOFLOW-II, -IV, and -V trials

	BIOFLOW-II	BIOFLOW-IV	BIOFLOW-V
<i>Clinical presentation</i>	Stable angina Unstable angina NSTEMI excluded STEMI excluded	Stable angina Unstable angina NSTEMI excluded STEMI excluded	Stable angina Unstable angina NSTEMI (hemodynamically stable) STEMI excluded
<i>Lesions</i>	1 or 2 de novo Length ≤ 26 mm RVD 2.5-3.75 mm Heavy calcification excluded LM excluded Bifurcation excluded Thrombus excluded CABG excluded	1 or 2 de novo Length ≤ 26 mm RVD 2.25-4.0 mm Heavy calcification excluded LM excluded Bifurcation excluded Thrombus excluded CABG excluded	Up to 3 de novo Length ≤ 36 mm RVD 2.25-4.0 mm Calcification not excluded* LM excluded Bifurcation lesion requiring 2-stent technique excluded Thrombus excluded CABG excluded
<i>LV function</i>	< 30% excluded	< 30% excluded	< 30% excluded

CABG, coronary artery bypass graft; LM, left main coronary artery; LV function, left ventricular function; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; RVD, reference vessel diameter.

*Atherectomy was allowed as long as adequate balloon predilatation was achieved.

Table 2 of the supplementary data. Clinical outcomes at 3 years

	None/mild tortuosity (n = 1447)	Moderate/severe tortuosity (n = 903)	<i>P</i> Log- rank	HR (95%CI)	<i>P</i>
Target lesion failure	122 (8.6)	85 (9.7)	.354	1.139 (0.863- 1.502)	.358
TV-MI	64 (4.5)	58 (6.5)	.031	1.469 (1.030- 2.096)	.034
cTLR	63 (4.5)	33 (3.9)	.447	0.849 (0.557- 1.294)	.447
Cardiac death	14 (1.0)	10 (1.2)	.690	1.179 (0.524- 2.655)	.691
Def/pro stent thrombosis	5 (0.4)	8 (0.9)	.084	2.582 (0.845- 7.892)	.096

TLF, target lesion failure; TV-MI, target vessel myocardial infarction; TLR, ischemia-driven target lesion revascularization; def/pro ST, definite and probable stent thrombosis.

Unless otherwise specified, the data are presented as No. (%).

Table 3 of the supplementary data. Univariable and multivariable analysis for target lesion failure, target vessel myocardial infarction and clinical indicated target lesion revascularization at 3 years

	Univariate analysis				Multivariate analysis				
TLF	HR	95%CI Lower	95%CI Upper	<i>P</i>		HR	95%CI Lower	95% CI Upper	<i>P</i>
Orsiro–BP-SES	0.674	0.512	0.888	.005	Orsiro–BP-SES	0.687	0.521	0.907	.008
Age	1.001	0.987	1.014	.908					
Hypertension	1.303	0.909	1.868	.149					
Hyperlipidemia	1.127	0.812	1.564	.476					
Diabetes mellitus	1.253	0.946	1.660	.115					
Renal insufficiency	1.608	1.051	2.461	.029	Renal insufficiency	1.679	1.096	2.574	.017
Cancer	1.075	0.678	1.704	.759					
Presentation in ACS	1.371	1.035	1.816	.028	Presentation in ACS	1.342	1.011	1.783	.042
Multivessel treatment	1.662	1.169	2.363	.005	Multivessel treatment	1.322	0.914	1.911	.138
Bifurcation lesion	1.375	0.952	1.986	.090	Bifurcation lesion	1.249	0.854	1.826	.252
Moderate/severe tortuosity	1.139	0.863	1.502	.358	Moderate/severe tortuosity	0.923	0.686	1.242	.599
Moderate/severe calcification	1.462	1.061	2.014	.020	Moderate/severe Calcification	1.336	0.951	1.876	.095
Lesion length > 20 mm	1.404	1.017	1.940	.039	Lesion length > 20 mm	1.303	0.934	1.818	.119
Ref. vessel diam ≤ 2.75 mm	1.596	1.180	2.158	.002	Ref. vessel diam ≤ 2.75 mm	1.545	1.133	2.108	.006

Cardiac death	HR	95%CI Lower	95%CI Upper	<i>P</i>		HR	95%CI Lower	95% CI Upper	<i>P</i>
Orsiro–BP-SES	0.842	0.369	1.924	.684					
Age	1.021	0.980	1.063	.325					
Hypertension	1.858	0.552	6.252	.317					
Hyperlipidemia	1.620	0.554	4.740	.378					
Diabetes mellitus	2.916	1.295	6.565	.110					
Renal insufficiency	5.055	2.096	12.189	< .001	Renal insufficiency	5.037	2.088	12.154	< .001
Cancer	2.036	0.696	5.957	.194					
Presentation in ACS	0.929	0.385	2.241	.870					
Multivessel treatment	2.380	0.945	5.995	.066	Multivessel treatment	2.358	0.931	5.971	.070
Bifurcation lesion	0.988	0.295	3.312	.984					
Moderate/severe tortuosity	1.179	0.524	2.655	.691	Moderate/severe tortuosity	1.078	0.476	2.439	.857
Moderate/severe calcification	1.257	0.469	3.367	.649					
Lesion length > 20 mm	1.210	0.452	3.241	.704					
Ref. vessel diam ≤ 2.75 mm	0.874	0.388	1.967	.744					
TV-MI	HR	95%CI	95%CI	<i>P</i>		HR	95%CI Lower	95%CI upper	<i>P</i>

Orsiro–BP-SES	0.654	0.457	0.935	.020	Orsiro–BP-SES	0.672	0.470	0.962	.030
Age	1.000	0.983	1.018	.962					
Hypertension	1.309	0.817	2.096	.263					
Hyperlipidemia	1.073	0.703	1.637	.745					
Diabetes mellitus	0.898	0.611	1.322	.586					
Renal insufficiency	1.199	0.646	2.229	.565					
Cancer	1.195	0.672	2.124	.543					
Presentation in ACS	1.506	1.048	2.163	.027	Presentation in ACS	1.434	0.997	2.063	.052
Multivessel treatment	2.158	1.415	3.291	< .001	Multivessel treatment	1.649	1.060	2.566	.026
Bifurcation lesion	1.959	1.277	3.004	.002	Bifurcation lesion	1.663	1.067	2.591	.025
Moderate/severe tortuosity	1.469	1.030	2.096	.034	Moderate/severe tortuosity	1.058	0.721	1.553	.772
Moderate/severe calcification	2.090	1.425	3.066	< .001	Moderate/severe Calcification	1.887	1.261	2.822	.002
Lesion length > 20 mm	1.363	0.894	2.078	.151					
Ref. vessel diam $\leq$ 2.75 mm	1.561	1.054	2.311	.026	Ref. vessel diam $\leq$ 2.75 mm	1.361	0.910	2.036	.133
TLR	HR	95%CI	95%CI	<i>P</i>		HR	95%CI Lower	95%CI upper	<i>P</i>
Orsiro–BP-SES	0.675	0.451	1.012	.057	Orsiro–BP-SES	0.677	0.452	1.015	.059
Age	0.997	0.978	1.017	.784					

Hypertension	1.514	0.873	2.627	.140					
Hyperlipidemia	1.414	0.847	2.361	.185					
Diabetes mellitus	1.563	1.043	2.342	.030	Diabetes mellitus	1.506	1.003	2.262	.049
Renal insufficiency	1.610	0.859	3.017	.137					
Cancer	0.788	0.365	1.700	.543					
Presentation in ACS	1.486	0.987	2.237	.058	Presentation in ACS	1.497	0.993	2.257	.054
Multivessel treatment	1.137	0.634	2.042	.667					
Bifurcation lesion	1.495	0.885	2.525	.132					
Moderate/severe tortuosity	0.849	0.557	1.294	.447	Moderate/severe tortuosity	0.759	0.496	1.161	.203
Moderate/severe calcification	1.325	0.817	2.150	.254					
Lesion length > 20 mm	1.299	0.801	2.108	.289					
Ref. vessel diam $\leq$ 2.75 mm	1.607	1.030	2.507	.037	Ref. vessel diam $\leq$ 2.75 mm	1.575	1.006	2.467	.047

BP-SES, bioresorbable-polymer sirolimus-eluting stent; ACS, acute coronary syndrome.